Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Location: United States
Employees: 11-50
Total raised: $405.5M
Founded date: 2020
Investors 6
| Date | Name | Website |
| 04.07.2025 | Avego | avego.com |
| - | Andera Par... | anderapart... |
| - | NFLS - Piv... | pivotalbio... |
| 11.07.2025 | B Capital ... | bcapgroup.... |
| - | SymBiosis | symbiosis.... |
| 18.04.2022 | Life Scien... | lspvc.com |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 07.11.2025 | IPO | $150M | - |
| 08.11.2024 | Series C | $115M | - |
| 28.06.2023 | Series B | $7.5M | - |
| 26.04.2023 | Series B | $50M | Amplitude ... |
| 09.09.2021 | Series A | $83M | Andera Par... |
Mentions in press and media 17
| Date | Title | Description |
| 07.11.2025 | NYSE Content Advisory: Pre-Market Update + Evommune Rises in Trading Debut | NEW YORK, Nov. 7, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scho... |
| 07.11.2025 | Andera Partners’ portfolio company Evommune successfully lists on New York Stock Exchange with a $150 million IPO | Andera Partners today announced that it participated in the $150 million IPO on NYSE of its portfolio company Evommune, demonstrating Andera’s continued support of the company’s value creation through clinical development and pipeline expan... |
| 06.11.2025 | NYSE Content Advisory: Pre-Market Update + Evommune & Aeromexico Begin Trading | NEW YORK, Nov. 6, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastr... |
| 09.11.2024 | Evommune Secures $115 Million to Tackle Chronic Inflammatory Diseases | In the bustling world of biotechnology, Evommune has made waves. The Palo Alto-based company recently secured $115 million in Series C financing. This funding is a lifeline, aimed at advancing their clinical-stage pipeline focused on immune... |
| 08.11.2024 | Evommune: $115 Million (Series C) Secured To Advance Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases | Evommune – a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases – announced the completion of a $115 million Series C financing. The funding was co-led by new investors RA... |
| 31.10.2024 | Evommune Raises $115M in Series C Financing | Evommune, a Palo Alto, CA-based clinical-stage biotechnology company focused on immune-mediated inflammatory diseases, raised $115M in Series C funding. The round was co-led by new investors RA Capital Management and Sectoral Asset Manageme... |
| 18.12.2023 | Pivotal bioVenture Partners closes $389M fund, bringing total commitments to $689M | Pivotal bioVenture Partners has closed its second fund of $389 million, money that will go toward North American and European companies working to develop new therapeutics. The fund brings the VC’s total capital commitments to $689 million.... |
| 30.06.2023 | Recent Digital Health Hires & Board Appointments | Theralink Technologies, Inc. appoints Faith Zaslavsky as its new Chief Executive Officer. Ms. Zaslavsky, who has served as the Company’s President and Chief Operating Officer since December 2022, will assume this role effective June 26, 202... |
| 28.06.2023 | Evommune Adds $7.5M to Series B Financing | Evommune, a Palo Alto, CA-based clinical-stage biotechnology company, raised additional $7.5M in Series B funding. The additional funding, which brought the total amount raised in the round to $57.5M, saw participation from Verition Fund Ma... |
| 26.04.2023 | Evommune Closes $50M Series B Financing | Evommune, a Palo Alto, CA-based clinical-stage biotechnology company, raised $50M in Series B funding. The round was led by co-led by new investor Arix Bioscience and current investors EQT Life Sciences and SymBiosis, with participation fro... |
Show more